<DOC>
	<DOCNO>NCT00296192</DOCNO>
	<brief_summary>The objective trial evaluate safety efficacy rotigotine nasal spray ( SPM 952 ) single dose application scheme . Subjects undergo 2 - 28 day screen period eligibility criterion check . Subjects hospitalize one night . In morning next day , subject randomly assign either rotigotine placebo nasal spray receive single dose trial medication . Safety assessment application include adverse event , 12-lead electrocardiogram , blood pressure heart rate assessment , laboratory check . Efficacy assessed application motor examination score . The first subject plan enrol February 2006 . The last subject plan enrol May 2006 . Last subject expect August 2006 .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability Rotigotine Nasal Spray Acute Treatment Parkinson Symptoms</brief_title>
	<detailed_description>The objective trial evaluate safety efficacy rotigotine nasal spray ( SPM 952 ) single dose application scheme . Subjects undergo 2-28 day screen period eligibility criterion check . Subjects hospitalize one night . In morning next day , subject randomly assign either rotigotine placebo nasal spray receive single dose trial medication . Safety assessment application include adverse event , 12-lead electrocardiogram , blood pressure heart rate assessment , laboratory check . Efficacy assessed application motor examination score .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Male female subject idiopathic Parkinson 's disease least 3 year duration At least 30 year age Patients atypical Parkinson 's clinically relevant concomitant diseases medical condition</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Rotigotine nasal spray</keyword>
	<keyword>Efficacy , safety tolerability</keyword>
	<keyword>Parkinson 's disease</keyword>
</DOC>